化疗所致周围神经毒性:患者自评与医生评估的前瞻性比较
该前瞻性观察研究纳入254例接受神经毒性化疗的成人患者,比较医生量表(TNSc、TNSn)与患者问卷(FACT/GOG-NTX)对化疗所致周围神经毒性(CIPN)的检测与分级。88%患者出现任何级别神经病变,三种工具反应性良好(标准化均值变化>1);在153例基线无神经病变者中,TNSc和TNSn与FACT/GOG-NTX中度相关(r=0.6),以FACT/GOG-NTX变化≥3.3分为临床重要阈值,TNSc的MCID为3.7、TNSn为2.8。
要点
- TNSc和TNSn与患者问卷FACT/GOG-NTX中度相关(r=0.6)。
- 以FACT/GOG-NTX变化≥3.3分为锚,TNSc的MCID为3.7、TNSn为2.8。
- 无法完成详细神经检查时,TNSn可作为可靠的客观临床替代评估。
核心结论
- TNSc和TNSn的MCID已计算,TNSn在无法进行更广泛神经检查时可作为可靠的替代客观临床评估。
- 患者自评问卷FACT/GOG-NTX与医生量表TNSc和TNSn中度相关。
研究设计与样本
- 前瞻性观察研究,连续纳入年龄≥18岁、拟接受神经毒性化疗的患者,来自美国、欧盟或澳大利亚。
- 由培训过的研究者执行医生量表(TNSc,并用于计算TNSn)并监督患者完成问卷FACT/GOG-NTX。
- 评估在化疗前和化疗结束时进行;在基线无神经病变的参与者中分析量表间关联。
- 共254例参与者数据可用,其中180例(71%)基线神经状态正常;153例基线无神经病变且接受已知神经毒性化疗方案者用于相关性分析。
主要发现
- 研究结束时88%的参与者出现任何级别的神经病变。
- TNSc、TNSn和FACT/GOG-NTX均显示良好反应性(从基线至化疗结束的标准化均值变化均>1)。
- 在153例基线无神经病变且接受已知神经毒性化疗方案者中,TNSc和TNSn评分与FACT/GOG-NTX呈中度相关(Spearman相关系数r=0.6)。
- 以FACT/GOG-NTX评分变化至少3.3分为临床重要阈值,TNSc的MCID为3.7,TNSn的MCID为2.8。
关键数值与推荐
- FACT/GOG-NTX评分变化≥3.3分被视为临床重要变化(基于先前建立的MCID)。
- TNSc的MCID为3.7,TNSn的MCID为2.8(以FACT/GOG-NTX变化≥3.3分为锚计算)。
- TNSc和TNSn与FACT/GOG-NTX的Spearman相关系数r=0.6。
- 所有量表从基线至化疗结束的标准化均值变化>1。
临床怎么用
- 在临床试验或临床实践中,若无法进行更广泛的神经检查,可使用TNSn作为客观临床评估的替代工具。
- 患者自评问卷FACT/GOG-NTX可与医生量表结合使用,以全面评估CIPN。
- TNSc和TNSn的MCID值(3.7和2.8)可用于解读临床变化的意义。
局限性
- 本研究提供Class III证据。
- MCID计算基于FACT/GOG-NTX变化≥3.3分的预设阈值。
- 相关性分析仅限于基线无神经病变且接受已知神经毒性化疗方案的153例参与者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: There is no agreement on the gold standard for detection and grading of chemotherapy-induced peripheral neurotoxicity (CIPN) in clinical trials. The objective is to perform an observational prospective study to assess and compare patient-based and physician-based methods for detection and grading of CIPN. METHODS: Consecutive patients, aged 18 years or older, candidates for neurotoxic chemotherapy, were enrolled in the United States, European Union, or Australia. A trained investigator performed physician-based scales (Total Neuropathy Score-clinical [TNSc], used to calculate Total Neuropathy Score-nurse [TNSn]) and supervised the patient-completed questionnaire (Functional Assessment of Cancer Treatment/Gynecologic Oncology Group-Neurotoxicity [FACT/GOG-NTX]). Evaluations were performed before and at the end of chemotherapy. On participants without neuropathy at baseline, we assessed the association between TNSc, TNSn, and FACT/GOG-NTX. Considering a previously established minimal clinically important difference (MCID) for FACT/GOG-NTX, we identified participants with and without a clinically important deterioration according to this scale. Then, we calculated the MCID for TNSc and TNSn as the difference in the mean change score of these scales between the 2 groups. RESULTS: Data from 254 participants were available: 180 (71%) had normal neurologic status at baseline. At the end of the study, 88% of participants developed any grade of neuropathy. TNSc, TNSn, and FACT/GOG-NTX showed good responsiveness (standardized mean change from baseline to end of chemotherapy >1 for all scales). On the 153 participants without neuropathy at baseline and treated with a known neurotoxic chemotherapy regimen, we verified a moderate correlation in both TNSc and TNSn scores with FACT/GOG-NTX (Spearman correlation index r = 0.6). On the same sample, considering as clinically important a change in the FACT/GOG-NTX score of at least 3.3 points, the MCID was 3.7 for TNSc and 2.8 for the TNSn. CONCLUSIONS: MCID for TNSc and TNSn were calculated and the TNSn can be considered a reliable alternative objective clinical assessment if a more extended neurologic examination is not possible. The FACT/GOG-NTX score can be reduced to 7 items and these items correlate well with the TNSc and TNSn. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that a patient-completed questionnaire and nurse-assessed scale correlate with a physician-assessed scale.
引用
- Alberti P, Bernasconi DP, Cornblath DR, et al. Prospective Evaluation of Health Care Provider and Patient Assessments in Chemotherapy-Induced Peripheral Neurotoxicity. Neurology. 2021. PMID: 34078718. doi:10.1212/WNL.0000000000012300
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。